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Vitamin D in chronic kidney 
disease: is the jury in?
Ian H. de Boer1 and Bryan Kestenbaum1
Vitamin D shows promise for improving diverse health outcomes among 
patients with chronic kidney disease. Observational studies of vitamin D 
medications have contributed important evidence for broad beneficial 
clinical effects of vitamin D beyond actions on bone. However, such 
studies are limited by the potential for confounding by indication. A 
large randomized controlled trial is now needed to test the hypothesis 
that vitamin D therapy improves clinical outcomes in patients with 
kidney disease.
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Vitamin D products have been used for 
nearly three decades to treat secondary 
hyperparathyroidism in patients with 
chronic kidney disease (CKD). Although 
bone health continues to be the primary 
motivation for prescribing vitamin D 
(cholecalciferol, ergocalciferol, calcitriol, 
and activated vitamin D analogues), inter-
est in the pleiotropic actions of vitamin D 
has recently taken center stage.1 Vitamin 
D receptors are present throughout the 
body in diverse tissues, and hundreds of 
human genes contain vitamin D response 
elements. Evidence for potential beneficial 
effects of vitamin D on immune function, 
cancer, and cardiovascular disease derives 
from experimental and animal models, 
associations of circulating vitamin D levels 
with health outcomes, nutritional epide-
miology, and ecological studies.
Pharmacoepidemiology studies— obser-
vational studies of medications— contrib-
ute additional evidence for broad beneficial 
clinical effects of vitamin D beyond actions 
on bone. Three large such studies have 
reported an approximately 20% lower 
risk of death among chronic hemodialysis 
patients treated with intravenous calcitriol 
or its analogues.2–4 Two smaller studies 
have observed 26% and 65% lower mor-
tality risks among predialysis CKD patients 
treated with oral calcitriol.5,6 Pharmacoepi-
demiology studies are more expedient and 
less expensive to conduct than randomized 
controlled trials (RCTs), and they provide 
additional opportunities to assess medica-
tion use in real-world settings. They often 
include individuals with multiple comorbid 
illnesses, who may be excluded from RCTs, 
and provide adequate follow-up time to 
evaluate clinically relevant end points and 
detect rare adverse effects.7
Naves-Díaz et al.8 (this issue) present 
results of a new pharmacoepidemiology 
study of vitamin D. The authors studied 
16,004 hemodialysis patients from six 
Latin American countries for a median of 
16 months. They found oral calcitriol use 
to be associated with a 45% reduction in 
relative risk for mortality. Similar benefi-
cial associations were observed for deaths 
due to cancer, infection, and cardiovascu-
lar disease, which were ascertained with 
International Classification of Disease-10 
codes. Importantly, the association of cal-
citriol use with survival was independent 
of circulating parathyroid hormone (PTH) 
concentrations. This finding is consist-
ent with prior studies2,5,6,9 and suggests 
that targeting vitamin D therapy to PTH 
may not be the most effective treatment 
strategy. Novel aspects of the study by 
Naves-Díaz et al.8 include a Latin Ameri-
can patient population, which may differ 
in terms of genetics, lifestyle factors, and 
practice patterns as compared with North 
American patients; assessment of mortal-
ity due to diverse causes; and evaluation 
in a hemodialysis population of oral cal-
citriol, which is widely available and rela-
tively inexpensive.
However, pharmacoepidemiology 
studies have an important limitation: the 
potential for confounding by indication. 
Patients and their physicians make indi-
vidualized decisions to initiate medica-
tions. These decisions often incorporate 
subtle aspects of health and health care that 
are not readily evident from information 
available in most studies. Confounding 
by indication occurs when the charac-
teristics of study subjects who receive a 
specific medication differ systematically 
from the characteristics of those who do 
not, and these differences, rather than the 
medication itself, affect clinical outcomes. 
Modern pharmacoepidemiology studies 
use many techniques that attempt to simu-
late an RCT and achieve a fair comparison 
of medication users with non-users. These 
techniques include restricting the study 
population to subjects with an indication 
for the drug of interest; studying incident 
(new) medication users to capture early 
events that may occur after initiation of 
therapy; accurately ascertaining medica-
tion use, subject characteristics, and pri-
mary outcomes; and analyzing subjects 
according to their initial medication use.7
Naves-Díaz et al.8 make laudable efforts 
to minimize confounding by indication. 
Nonetheless, available data limit their abil-
ity to comprehensively address this poten-
tial limitation. First, ‘baseline’ participant 
characteristics were obtained from initial 
study enrollment and may not accurately 
reflect current health status at the time of 
calcitriol initiation. Second, the available 
data sources do not permit precise ascer-
tainment of comorbid conditions and 
socioeconomic status. Third, prevalent 
and incident calcitriol users were com-
bined, potentially obscuring early effects 
of calcitriol. Finally, a non-trivial propor-
tion of study subjects (11%) were censored 
for reasons that may introduce bias (for 
example, transplantation, change in renal 
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replacement modality, withdrawal from 
dialysis, or recovery of renal function). 
One must question whether the observed 
45% reduction in mortality, which is larger 
than most previous studies report2–5 and 
may appear ‘too good to be true,’ reflects, 
in part, residual confounding.
What are we to conclude? Observational 
studies may refine our understanding of 
vitamin D but cannot provide definitive 
evidence of clinical benefit. Instead, a 
well-designed RCT of vitamin D in CKD 
is needed to address whether vitamin D 
affects clinical health outcomes in this 
patient population (Figure 1). RCTs over-
come many potential biases of observa-
tional studies and are the gold standard 
for evaluating the clinical effectiveness of 
medical interventions. Historical compari-
sons encourage humility: observational 
data, supported by biologic plausibility, 
strongly suggested that estrogen replace-
ment therapy and vitamin E each pre-
vented cardiovascular disease, but RCTs 
demonstrated a lack of benefit or even 
harm from these interventions.
An RCT of vitamin D in CKD is justified 
because large potential benefits (survival) 
and costs (pharmaceutical expenditures) 
are at stake, and because we remain in a 
state of equipoise. The sum of existing data 
suggests that vitamin D treatment may 
improve survival in CKD, but these data are 
neither conclusive nor sufficient to deter-
mine optimal clinical care. Additional stud-
ies that examine intermediate end points, 
such as change in cardiovascular risk fac-
tors or immune function, may be useful by 
providing biologic plausibility to support 
the associations described in observational 
studies. However, because vitamin D may 
have diverse effects on many organs, ben-
eficial effects on one biologic end point may 
counterbalance adverse effects elsewhere, 
or vice versa. Only a large trial examining 
broad clinical end points such as mortality 
or cardiovascular events can capture the full 
clinical impact of vitamin D treatment.
A number of unique issues make design 
of a successful trial of vitamin D in CKD 
particularly challenging. First is the choice 
of study population(s). The hemodialysis 
population is attractive because it is read-
ily identifiable for recruiting; therapy can 
be directly administered during treatment 
sessions, reducing potential for nonadher-
ence; and hemodialysis patients experi-
ence an unacceptably high mortality rate, 
both motivating definition of optimal 
interventions and decreasing the sample 
size necessary for a clinical trial. However, 
the hemodialysis population is complex 
because of highly prevalent use of calcitriol, 
paricalcitol, various phosphate binders, and 
calcimimetics. In addition, existing guide-
lines specify that treatments be directed to 
PTH, despite a lack of compelling evidence 
that this approach improves clinical out-
comes. These issues may be minimized by 
targeting of incident hemodialysis patients. 
Alternatively, an RCT could target stage 
3–4 CKD. Stage 3–4 CKD affects many 
more people than end-stage renal disease, 
the use of medications affecting mineral 
metabolism is currently less common in 
this population, and two studies suggest 
that the relative effects of vitamin D on 
mortality are similar to those observed in 
end-stage renal disease.5,6
Second, multiple potential interven-
tions exist. Calcitriol and its analogues 
have differential effects in various tissues. 
However, the exact mechanisms through 
which vitamin D may reduce mortality are 
not known; this precludes confident selec-
tion of a single superior vitamin D agent. 
In addition, there is increasing interest 
in potential paracrine and/or autocrine 
effects of vitamin D,1 which may be best 
activated by administration of a substrate 
form of vitamin D (cholecalciferol or ergo-
calciferol). Cholecalciferol or ergocalcif-
erol could be given in combination with 
an activated form of vitamin D or could be 
tested in a separate treatment arm.
Third, control interventions will be con-
troversial. A placebo control would opti-
mize identification of any vitamin D effect, 
but higher PTH levels in a placebo group 
may generate ethical concerns and/or dif-
ferential use of other medications to lower 
PTH. Alternative designs to a placebo con-
trol, such as fixed vitamin D dose versus 
vitamin D titrated to PTH, or vitamin D 
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Figure 1 | Reseach on Vitamin D in chronic kidney disease. Observational studies (a) have 
developed a strong rationale for further investigating the clinical effects of vitamin D in chronic 
kidney disease (b). A large randomized clinical trial is needed to test whether vitamin D truly 
improves health outcomes. Such a trial faces unique design challenges (c).
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versus calcimimetic, will not directly test 
the scientific question at hand. These issues 
will be particularly relevant if the Evalua-
tion of Cinacalcet Therapy to Lower Car-
diovascular Events trial demonstrates an 
effect of cinacalcet on mortality.10
Finally, RCTs are expensive. The design 
issues outlined above are subtle and com-
plex, with potential for conflicts between 
patient benefits and corporate marketing 
strategies. Public funding will be required 
to ensure that trial results maximally 
benefit patients.
Diverse and creative research by the 
nephrology community has generated 
renewed interest in vitamin D. We are cur-
rently challenged with the task of trans-
lating exciting discovery into improved 
clinical care for our patients. Pharmaco-
epidemiology studies have added critical 
data regarding the potential beneficial 
effects of vitamin D therapy in CKD. A large 
RCT is now needed to test the hypothesis 
that vitamin D therapy improves clinical 
outcomes in patients with kidney disease.
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The hunt for the perfect biomarker 
for acute kidney injury:  
back to gamma-trace?
Josephine P. Briggs1
The hunt for a good biomarker for acute kidney injury (AKI) is currently hot. 
It has recently been the subject of several excellent reviews1–3 and a useful 
meta-analysis,4 and we are hearing exhortations that this hunt should 
get high priority.3,5 The ideal marker (or set of markers) should facilitate 
early identification, stratify risk, and contribute to informative diagnostic 
classification. Perhaps most importantly, a good marker should aid the 
testing of interventions to prevent development of AKI and improve 
management. So, there are very good reasons to get on with it!
Kidney International (2008) 74, 987–988. doi:10.1038/ki.2008.426
While the practical arguments are per-
suasive, a secondary benefit of acute 
kidney injury (AKI) biomarker research 
will also be new basic understanding. An 
intriguing example is the recent paper by 
Ichimura and co-workers on KIM-1, one 
of the current candidate AKI biomark-
ers.6 In a study published in May 2008 in 
the Journal of Clinical Investigation, these 
investigators show that injured proximal 
tubule cells develop phagocytic capacity 
and become macrophage-like in their 
behavior. KIM-1, an epithelial cell surface 
protein upregulated by injury and shed 
into the urine by damaged cells, appears 
to play a causal role in this transforma-
tion. The finding that epithelial cells can 
acquire a phagocytic phenotype is unex-
pected and potentially important for tis-
sue repair and recovery.
In this issue of Kidney International, 
Koyner and co-workers7 report data on 
another current candidate, urinary cysta-
tin C. This study also raises biological 
questions and reminds us that that there 
are important unanswered questions 
about the renal biology of cystatin C. 
Cystatin C has a curious history. Serum 
cystatin C is getting all the attention these 
days for its potential utility for the esti-
mation of glomerular filtration rate. But 
cystatin C was actually first identified not 
as a serum marker but as a urinary marker. 
In 1961 Frederick Flynn, a clinical pathol-
ogist at University College Hospital, and 
Elizabeth Butler, a nurse at the same insti-
tution, reported a novel protein in urine 
of patients with proteinuria, which they 
called post-gamma protein because of its 
position after γ-globulins on an electro-
phoretic gel.8 In the ‘biomarker’ literature 
of that period, gamma-trace, as it came 
to be called, was placed in the group of 
low–molecular weight proteins associated 
with ‘tubular’ injury, hence part of ‘tubu-
lar’ proteinuria. Flynn and Platt argued 
that the presence of small proteins such as 
gamma-trace in urine reflected a failure of 
proximal reabsorption of freely filterable 
proteins,9 a question still of interest and 
still in need of further study.
The next chapter in the gamma-trace/
cystatin C story takes place in Sweden 
about 20 years later. The key investiga-
tors were two clinical pathologists at the 
University of Lund in Sweden, Anders 
Grubb and Helge Löfberg. They pursued 
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